You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Case of adult large vessel vasculitis after SARS-CoV-2 infection
  1. Ryohei Oda1,
  2. Takeshi Inagaki1,
  3. Masahiro Ishikane2,
  4. Masatoshi Hotta3,
  5. Akira Shimomura1,
  6. Mitsuhiro Sato2,
  7. Takato Nakamoto2,
  8. Yutaro Akiyama2,
  9. Kei Yamamoto2,
  10. Ryogo Minamimoto3,
  11. Hiroshi Kaneko4,
  12. Norio Ohmagari2
  1. 1 General Medicine, National Center for Global Health and Medicine, Shinjuku-ku, Japan
  2. 2 Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Japan
  3. 3 Radiology, National Center for Global Health and Medicine, Shinjuku-ku, Japan
  4. 4 Department of Rheumatic Diseases, National Center for Global Health and Medicine, Shinjuku-ku, Japan
  1. Correspondence to Dr Takeshi Inagaki, General Medicine, National Center for Global Health and Medicine, Shinjuku-ku, Japan; tinagaki{at}hosp.ncgm.go.jp

http://dx.doi.org/10.1136/annrheumdis-2020-218440

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest the article ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al.1 This study showed that glucocorticoid exposure of ≥10 mg/day was associated with higher odds of hospitalisation and anti-TNF with a decreased odds of hospitalisation in patients with COVID-19 with rheumatic disease. Like this report, studies on the relationship between COVID-19 and rheumatic diseases are needed. Although several cases of vasculitis, such as large vessel vasculitis (LVV) and Kawasaki disease, have been reported among patients with COVID-19,2 3 there are no recorded cases of adult LVV developing after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We report a case of this development.

    A 71-year-old Japanese man was admitted to our hospital with complaints of fever and productive cough for 12 days. He was referred to our hospital after a chest X-ray at a private clinic revealed ground glass opacity (GGO) in bilateral lung fields. He had no history of vasculitis or arteriosclerosis. Two days after admission, PCR was positive for SARS-CoV-2 RNA. He was …

    View Full Text

    Footnotes

    • RO and MI are joint first authors.

    • RO and MI contributed equally.

    • Correction notice This article has been corrected since it published Online First. Figure 1 legend has been corrected.

    • Contributors RO and MI drafted the manuscript, and all authors contributed substantially to its revision. TI takes responsibility for the paper as a whole.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

    • Provenance and peer review Not commissioned; internally peer reviewed.